Jump to content

Cisplatin and CBT-11 (or is it CPT-11) for SCLC

Recommended Posts

Hi, ya'll, for more background, see our post under General (it's back) but Dave's oncologist told us about great progress they're making in Japan using combo of cisplatin and CBT-11 together for SCLC. He said that combo is in clinical trials in the U.S. for first line treatment but since this is a mets for Dave he wouldn't be in a trial, but the onc. (who is really great, brilliant, caring, up to date on everything) want to use it for Dave, he seemed quite excited about it actually.

He said it's been used in Japan but still in the clinical trial stage in the U.S. but I get the feeling he's seen enough evidence of how well it's working that he wants to use it with Dave.

Just wondering if anyone knows much more about this.


Karen C.

Link to comment
Share on other sites

I would ask the doctor what is his take on the MDR (multidrug resistance gene (MRP1), P-glycoprotein, Glutathione S-transferases. What are the trials available if any based on MDR

There are a few drugs in clinical trials to fight MDR but none are proven and I am not sure how they are doing in the trials.

The drugs are called Tariguidar and TLK286.

The first 3 things are hypothesized to cause multiple drug resistance. I don't know how good the research is but it might be something to ask.

Whey protein is "supposed" to make cancer cells more suceptible to chemo. It is supposed to deplete the cancer cells of glutatione.

This information is definitely experimental and you have to do some research on your own. But you might want to look at "whey protein" and cancer. Again, the level of evidence is probably not high.

Anticancer Res. 1995 Nov-Dec;15(6B):2643-9. Related Articles, Links

The use of a whey protein concentrate in the treatment of patients with metastatic carcinoma: a phase I-II clinical study.

Kennedy RS, Konok GP, Bounous G, Baruchel S, Lee TD.

Department of Surgery, Dalhousie University, Halifax, Nova Scotia, Canada.

Glutathione (GSH) concentration is high in most tumour cells and this may be an important factor in resistance to chemotherapy. Previous in-vitro and animal experiments have shown a differential response of tumour versus normal cells to various cysteine delivery systems. More specifically, an in-vitro assay showed that at concentrations that induce GSH synthesis in normal human cells, a specially prepared whey protein concentrate, Immunocal, caused GSH depletion and inhibition of proliferation in human breast cancer cells. On the basis of this information five patients with metastatic carcinoma of the breast, one of the pancreas and one of the liver were fed 30 grams of this whey protein concentrate daily for six months. In six patients the blood lymphocyte GSH levels were substantially above normal at the outset, reflecting high tumour GSH levels. Two patients (#1, #3) exhibited signs of tumour regression, normalization of haemoglobin and peripheral lymphocyte counts and a sustained drop of lymphocyte GSH levels towards normal. Two patients (#2, #7) showed stabilisation of the tumour, increased haemoglobin levels. In three patients (#4, #5, #6,) the disease progressed with a trend toward higher lymphocyte GSH levels. These results indicate that whey protein concentrate might deplete tumour cells of GSH and render them more vulnerable to chemotherapy.

Link to comment
Share on other sites

  • 2 weeks later...

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.